Combination vildagliptin and metformin can improve glycemic control in Japanese patients with type 2 diabetes mellitus (T2DM) without inducing tolerability issues or hypoglycemia, a new study suggests.
In a multicenter, double-blind trial conducted by Masato Odawara, MD, PhD, and colleagues at Tokyo Medical University, 139 T2DM patients on metformin were randomized to receive either vildagliptin (69 patients) or placebo (70 patients) for 12 weeks. The vildagliptin recipients had an adjusted mean 1.1% decline in hemoglobin A1c (HbA1c) after treatment compared with a 0.1% decline in the placebo group, the researchers reported online ahead of print in Diabetes Therapy.
Additionally, a significantly higher proportion of patients in the vildagliptin than the placebo arm had HbA1c target levels of 6.5% or below (30.9% vs. 2.9%) and less than 7.0% (64.1% vs. 15.3%). The vildagliptin and placebo groups had similar incidences of adverse effects (44.1% vs. 41.4%). No deaths or hypoglycemic events were reported.